Reducing agent-mediated precipitation of high-abundance plasma proteins

Warder, Scott E.; Tucker, Lora; Strelitzer, Tamara J.; McKeegan, Evelyn; Meuth, Joseph L.; Jung, Paul; Saraf, Anita; Singh, Bhawani; Lai-Zhang, Jie; Gagné, Geneviève; Rogers, John C.

doi:10.1016/j.ab.2009.01.013

Cited by 55 publications

(44 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The solubility of some proteins, including apolipoprotein A1, alpha 1 antitrypsin and transthyretin, improved for example at pH 11, while a low level of albumin recovery persisted (unpublished results). Another straightforward method of HAP removal is the reducing agent mediated precipitation method [33]. However, comparisons between these methods showed that HAP removal was more efficient when an ACN-precipitation step was performed [34].…”

Section: Sample Preparation and Analyte Enrichmentmentioning

confidence: 98%

Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?

Lehmann

Brede

Lescuyer

et al. 2017

Clinica Chimica Acta

View full text Add to dashboard Cite

Section: Sample Preparation and Analyte Enrichmentmentioning

confidence: 98%

Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?

Lehmann

Brede

Lescuyer

et al. 2017

Clinica Chimica Acta

View full text Add to dashboard Cite

“…New advances in mass spectrometry (MS) and protein microarray technology have reduced the threshold for protein detection to sub-nanogram levels [30]. Several strategies have also been developed for the depletion of highly abundant proteins and for enriching lowconcentration proteins, including different immunoaffinity Clin Exp Metastasis (2010) 27:441-451 443 [25,32,[37][38][39][40][41]. One important drawback of these methods is that several low abundance proteins or peptides, which are complexed to blood carrier proteins, such as albumin, are lost [33].…”

Section: Principal Considerations About Biomarker Researchmentioning

confidence: 99%

Proteomic strategies and challenges in tumor metastasis research

Hudler

Gorsic

Komel

2010

Clin Exp Metastasis

View full text Add to dashboard Cite

The rapidly evolving field of proteomics offers new approaches to understanding the pathogenesis of cancer and metastatic disease. Although numerous tumor markers have been identified with different genomic methods in the past, most are either not specific or sensitive enough to be used in routine clinical setting. The rationale for proteomic profiling is based on the fact that proteins represent the dynamic state of the cells, reflecting pathophysiological changes in the disease more accurately than genomic and epigenetic alterations. Emerging proteomic techniques allow simultaneous assessment of a large number of proteins at one time. The study of protein profiles in complex systems, such as plasma, serum or tissues of cancer patients is likely to become valuable for monitoring the response of patients during treatment or for detecting recurrence of the disease.

show abstract

“…The hydrophobic groups can also interact with each other to form intermolecular hydrophobic bonds further catalyzing aggregation and co-precipitation with abundant UEVs attached. This mechanism is plausible and was recently exploited to deplete plasma from high abundant disulfide-rich proteins for mass spectrometry analysis (96). …”

Section: Bottlenecks Of Uev Isolation and Future Aspectsmentioning

confidence: 99%

Use and Isolation of Urinary Exosomes as Biomarkers for Diabetic Nephropathy

2014

View full text Add to dashboard Cite

Diabetes represents a major threat to public health and the number of patients is increasing alarmingly in the global scale. Particularly, the diabetic kidney disease (nephropathy, DN) together with its cardiovascular complications cause immense human suffering, highly increased risk of premature deaths, and lead to huge societal costs. DN is first detected when protein appears in urine (microalbuminuria). As in other persisting proteinuric diseases (like vasculitis) it heralds irreversible damage of kidney functions up to non-functional (end-stage) kidney and ultimately calls for kidney replacement therapy (dialysis or kidney transplantation). While remarkable progress has been made in understanding the genetic and molecular factors associating with chronic kidney diseases, breakthroughs are still missing to provide comprehensive understanding of events and mechanisms associated. Non-invasive diagnostic tools for early diagnostics of kidney damage are badly needed. Exosomes – small vesicular structures present in urine are released by all cell types along kidney structures to present with distinct surface assembly. Furthermore, exosomes carry a load of special proteins and nucleic acids. This “cargo” faithfully reflects the physiological state of their respective cells of origin and appears to serve as a new pathway for downstream signaling to target cells. Accordingly, exosome vesicles are emerging as a valuable source for disease stage-specific information and as fingerprints of disease progression. Unfortunately, technical issues of exosome isolation are challenging and, thus, their full potential remains untapped. Here, we review the molecular basis of exosome secretion as well as their use to reveal events along the nephron. In addition to novel molecular information, the new methods provide the needed accurate, personalized, non-invasive, and inexpensive future diagnostics.

show abstract

Reducing agent-mediated precipitation of high-abundance plasma proteins

Cited by 55 publications

References 49 publications

Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?

Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?

Proteomic strategies and challenges in tumor metastasis research

Use and Isolation of Urinary Exosomes as Biomarkers for Diabetic Nephropathy

Contact Info

Product

Resources

About